Sorrento Therapeutics Inc. has published data on the identification, in vitro binding and neutralizing activity of a novel monoclonal antibody (MAb), STI-5041, against the SARS-CoV-2 WA-1 strain as well as the alpha and beta variants from their G-MAB library screening.
The University of Arizona has divulged nonstructural protein 3 (Nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
CEPI, the Coalition for Epidemic Preparedness Innovations, will provide seed funding of up to $4.8 million to Intravacc BV to advance the development of a broadly protective betacoronavirus vaccine candidate, which can be delivered intranasally.
Covira Inc., a spinout from The University of Chicago, has closed its first dilutive funding via an oversubscribed $1.0 million seed round after raising $9.1 million of nondilutive funding.
Revelation Biosciences Inc. has entered into an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD) for treating or preventing infections.
Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of Porphyromonas gingivalis infection.
Intravacc BV has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG), the cause of the sexually transmitted disease gonorrhea.
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection.
Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
RSS
